【藥品性質提示】 #高警訊藥品 【藥品訊息】 Tresiba 胰島素筆 草綠 衛教單張

糖尿病 (基礎胰島素) Diabetes mellitus, type 1 and type 2

Long-Acting Insulin
Insulin acts via specific membrane-bound receptors on target tissues to regulate metabolism of carbohydrate, protein, and fats. Target organs for insulin include the liver, skeletal muscle, and adipose tissue.

1. Onset: ~1 hour
2. Protein binding: >99% (albumin)
3. Half-life elimination: ~25 hours (independent of dose)
4. Time to peak: 9 hours

Hypersensitivity to insulin degludec or any component of the formulation; during episodes of hypoglycemia.

Agents other than insulin degludec are currently recommended to treat diabetes mellitus in pregnancy

Both exogenous and endogenous insulin are present in breast milk.

Endocrine & metabolic: Severe hypoglycemia (type 1 diabetics on combination insulin therapy: 10% to 18%; type 2 diabetics on combination therapy: ?5%)
Immunologic: Antibody development
Nervous system: Headache (9% to 12%)
Respiratory: Nasopharyngitis (13% to 24%), upper respiratory tract infection (8% to 12%)

Diabetes mellitus, type 1: SUBQ
1. Initial TDD: 0.4 to 0.5 units/kg/day; conservative initial doses of 0.2 to 0.4 units/kg/day may be considered to avoid hypoglycemia
2. Usual TDD maintenance range: 0.4 to 1 units/kg/day in divided doses
Diabetes mellitus, type 2: SUBQ
1. Initial: 10 units once daily or 0.1 to 0.2 units/kg once daily
2. In patients with HbA1c >8%, fasting plasma glucose >250 mg/dL, or insulin resistance: 0.2 to 0.3 units/kg/day (up to 15 to 20 units/day)
3. For persistently elevated fasting plasma glucose: Increase daily dose by 2 to 4 units or by 10% to 20% every 3 to 7 days
4. For hypoglycemia: Consider decreasing daily dose by 10% to 20%; for severe hypoglycemia requiring assistance from another person or blood glucose <40 mg/dL, consider reducing dose by 20% to 50%

There are no dosage adjustments provided in the manufacturer's labeling; insulin requirements may be reduced due to changes in insulin clearance or metabolism; monitor blood glucose closely.

There are no dosage adjustments provided in the manufacturer's labeling; insulin requirements may be reduced due to changes in insulin clearance or metabolism; monitor blood glucose closely.